Acumen Pharmaceuticals (ABOS) Payables (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Payables data on file, last reported at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 1394.13% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $15.8 million (up 1394.13% YoY), and the FY2025 full-year result was $9.3 million, up 65.0% from the prior year.
• Payables rose to $15.8 million in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $15.8 million in Q1 2026 to a low of $762000.0 in Q1 2023.
• A 5-year average of $3.5 million and a median of $2.1 million in 2022 frame the typical range for Payables.
• Across the five-year window, Payables sank 65.7% in 2025 and jumped 1394.13% in 2026, its largest moves.
• Tracing ABOS's Payables over 5 years: stood at $1.6 million in 2022, then retreated by 15.91% to $1.4 million in 2023, then soared by 309.57% to $5.6 million in 2024, then surged by 65.0% to $9.3 million in 2025, then surged by 69.31% to $15.8 million in 2026.
• Business Quant data shows ABOS's Payables at $15.8 million in Q1 2026, $9.3 million in Q4 2025, and $4.3 million in Q3 2025.